Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given New $3.00 Price Target at Maxim Group

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price target reduced by Maxim Group from $5.00 to $3.00 in a report issued on Friday morning,Benzinga reports. Maxim Group currently has a buy rating on the stock.

A number of other equities analysts have also issued reports on LCTX. HC Wainwright boosted their target price on shares of Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. D. Boral Capital restated a “buy” rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Friday, January 3rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lineage Cell Therapeutics has an average rating of “Buy” and a consensus price target of $4.80.

Lineage Cell Therapeutics Price Performance

LCTX stock opened at $0.58 on Friday. The stock has a market cap of $127.84 million, a price-to-earnings ratio of -4.83 and a beta of 1.16. Lineage Cell Therapeutics has a 52-week low of $0.48 and a 52-week high of $1.61.

Institutional Investors Weigh In On Lineage Cell Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new stake in shares of Lineage Cell Therapeutics in the 3rd quarter worth about $46,000. XTX Topco Ltd bought a new stake in Lineage Cell Therapeutics during the second quarter worth about $61,000. GSA Capital Partners LLP acquired a new stake in shares of Lineage Cell Therapeutics during the third quarter worth approximately $84,000. Rhumbline Advisers raised its stake in shares of Lineage Cell Therapeutics by 15.1% in the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock valued at $132,000 after acquiring an additional 17,411 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Lineage Cell Therapeutics by 311.3% in the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after acquiring an additional 159,924 shares in the last quarter. 62.47% of the stock is owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.